iRhythm director sold 5,312 shares; options exercised at $10.71 under 10b5-1 plan
Rhea-AI Filing Summary
iRhythm Technologies director Abhijit Talwalkar executed a Rule 10b5-1 trading plan on August 11, 2025. He exercised employee stock options to acquire 5,312 shares at an exercise price of $10.71 and then sold those shares in two series: 3,183 shares at a weighted-average price of $157.5723 and 2,129 shares at a weighted-average price of $158.6792. The reported sale price ranges were $157.2350–$158.1800 and $158.3100–$159.0000. Following these transactions, his beneficial ownership is reported as 20,299 shares. The option exercised was originally granted May 23, 2016 and expires May 23, 2026.
Positive
- Transactions were executed pursuant to a Rule 10b5-1 trading plan established May 12, 2025
- Option exercise details provided: 5,312 shares exercised at a $10.71 strike
- Filing discloses weighted-average sale prices and exact sale price ranges
Negative
- Director sold a total of 5,312 shares on August 11, 2025 (3,183 and 2,129 shares)
- Reported beneficial ownership declined to 20,299 shares after the transactions
Insights
TL;DR: Director used a pre-established 10b5-1 plan to exercise options and sell shares, leaving 20,299 shares outstanding.
The filings show a contemporaneous exercise of 5,312 option shares at a $10.71 strike and subsequent sales executed the same day under a Rule 10b5-1 plan established May 12, 2025. Sales were executed in two blocks at weighted-average prices of $157.5723 and $158.6792, with reported price ranges for the transactions. The net effect reduced reported beneficial ownership from the pre-transaction level to 20,299 shares. This disclosure is factual and routine for scheduled insider liquidity events.
TL;DR: Transactions were performed under a documented 10b5-1 plan and include option exercise details and expiration information.
The Form 4 confirms the transactions were effected pursuant to a Rule 10b5-1 trading plan established May 12, 2025, and provides option grant and expiration details: the exercised option was granted May 23, 2016 for 21,248 shares, vested monthly, and expires May 23, 2026. The report is signed by an attorney-in-fact and includes weighted-average sale prices and ranges, meeting typical disclosure requirements for insider trades.